BRAF wild-type

Given the tumour's unresectable nature due to proximity to critical mediastinal structures and the patient's comorbidities, she was initiated on a modified combination immune checkpoint inhibitor regimen with nivolumab and ipilimumab. This case highlights the importance of a meticulous diagnostic approach to solitary pulmonary lesions and underscores the evolving role of immunotherapy in managing rare malignancies such as PMML. Reporting such cases enhances the clinical understanding and guides future management of this rare disease.

We present the largest dataset on melanoma BRAF status in England. These findings underscore the importance of incorporating BRAF testing into -early-stage melanoma care, ensuring early and accurate testing to guide treatment and improve understanding of patient prognosis.

P2, N=169, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jan 2025

ERBB2 amp+ mCRC is a small but clinically relevant subgroup with inferior rwPFS across current first-line treatments, highlighting the need for better strategies.

This case underscores the importance of comprehensive assessment integrating tumor and germline molecular data, particularly when clinical or molecular findings are atypical or discordant. The digenic etiology also raises questions regarding cancer surveillance and management strategies in such individuals.

The exploratory analysis of FIRE-3 suggests that the efficacy of cetuximab combined with FOLFIRI in RAS wild-type mCRC is related to sex and primary tumor sidedness. The results support the inclusion of patient sex into the design of future trials.

Pyrotinib plus trastuzumab demonstrates clinically meaningful efficacy and a manageable safety profile in heavily pretreated HER2-positive metastatic colorectal cancer. These findings support advancing this regimen as a potential alternative in refractory HER2-positive mCRC, particularly in the RAS/BRAF wild-type subgroup.

BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.

Most cases lack germline MMR mutations in normal tissues but harbor somatic MMR mutations in tumor tissues. Germline or somatic mutations in other genes related to MMR function may be observed in some cases.

Our study provides a comprehensive genetic and molecular profile that closely recapitulates human diabetes. This system offers a valuable avenue for advancing basic research in the field of inflammation and regeneration within a diabetic context and promotes translational research for diabetes therapy.

The results showed that FOLFOXIRI combined with bevacizumab and atezolizumab significantly improved PFS and OS, with HRs for PFS and OS of (HR:0.19, 95% CI: 0.11-0.33), (HR:0.48, 95% CI: 0.30-0.78), respectively...These findings underscore the importance of integrating targeted drugs and immunotherapy in first-line mCRC treatments, highlighting significant differences in efficacy and safety profiles that can guide therapeutic decisions. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024604107, identifier CRD42024604107.

P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Dec 2025 --> Jul 2025